Trusopt

Trusopt 2% Ophthalmic Solution: Effective Relief for Elevated Intraocular Pressure

Trusopt 2% Ophthalmic Solution is a sterile, isotonic, buffered, slightly viscous aqueous solution designed to treat elevated intraocular pressure in patients with ocular hypertension and open-angle glaucoma. This solution contains dorzolamide hydrochloride, a potent inhibitor of human carbonic anhydrase II, which works by reducing aqueous humor secretion in the ciliary processes of the eye. This reduction in aqueous humor secretion leads to a decrease in intraocular pressure (IOP), a major risk factor for optic nerve damage and visual-field loss.

Unlike oral carbonic anhydrase inhibitors, Trusopt is administered topically and exerts its effects directly in the eye, minimizing systemic exposure. It is indicated as adjunctive therapy to beta-blockers or as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated.

Trusopt does not cause pupillary constriction and reduces IOP without common adverse effects like night blindness or accommodative spasm. Each milliliter of Trusopt 2% contains 20 mg of dorzolamide, and it is supplied in a 5-milliliter translucent plastic dispensing bottle with an opaque white cap. The solution is clear, colorless to nearly colorless, and slightly viscous, making it easy to administer. Benzalkonium chloride 0.0075% is added as a preservative to ensure the solution remains effective and safe to use.

Trusopt has been demonstrated to be effective in clinical studies, showing significant reductions in IOP throughout the day and maintaining its effect during long-term administration. It is a reliable option for managing elevated intraocular pressure and preventing associated complications.